We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Ed Ballard
LONDON--AstraZeneca PLC (AZN.LN) Monday said European regulators have approved Duaklir Genuair, an inhaler treatment for chronic obstructive pulmonary disease.
The European Commission cleared the drug for use by adults after studies of its effects on more than 2,000 patients in 11 clinical studies demonstrated that it improved lung function compared to competitor drugs, AstraZeneca said.
"AstraZeneca owns the rights to develop and commercialize Duaklir Genuair in the European Union following the strategic business combination of Almirall's respiratory portfolio, which was completed last month," the Anglo-Swedish drug company said.
"The E.U. approval of Duaklir Genuair marks an important further step in AstraZeneca's inhaled-therapy strategy of providing physicians and patients a choice of products uniquely available in both dry powder and pressurised metered dose devices," it said.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
